JAK3-IN-20

JAK3-IN-20 (Compound 7n) (60 min) potently inhibits purified JAK3 protein with an IC₅₀ of 0.7473 nM^[1].
JAK3-IN-20 (5 nM) shows high selectivity for JAK3, with 96.87% inhibition at 5 nM, and only moderate inhibition of JAK2 and TYK2, with no significant activity against JAK1^[1].
JAK3-IN-20 (72 h) potently inhibits proliferation of Bortezomib (HY-10227)-resistant KM3 multiple myeloma cells with an IC₅₀ of 0.245 μM, and also inhibits proliferation of KM3, BaF3-JAK3, Raji, Paca-02, H1975, HK-2, and LX-2 cells with IC₅₀ values of 0.211-4.317 μM^[1].
JAK3-IN-20 (0.3125-5.0 μM; 48 h) induces dose-dependent apoptosis and G2/M phase arrest in Bortezomib-resistant KM3 multiple myeloma cells^[1].
JAK3-IN-20 (78.13-312.5 nM; 48 h) dose-dependently inhibits migration of Bortezomib-resistant KM3 multiple myeloma cells^[1].
JAK3-IN-20 (0.3125-5.0 μM; 48 h) dose-dependently upregulates pro-apoptotic Bax protein and downregulates anti-apoptotic Bcl-2 protein in Bortezomib-resistant KM3 multiple myeloma cells^[1].
JAK3-IN-20 (15.6 nM-4 μM; 1-72 h) dose-dependently inhibits STAT5 phosphorylation in Bortezomib-resistant KM3 multiple myeloma cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.